News archives

Home > News archives > Completion of the Series C funding to advance pipeline of novel GPCR antibodies

Completion of the Series C funding to advance pipeline of novel GPCR antibodies

Apr 27,2022 -- Updated 22:50 +0900 (GMT)

NBHL has completed 7.64 million USD of the Series C funding to advance pipeline of novel GPCR antibodies.

Click here for detail.